(Lincoln University, 2026) Wright, Benjamin
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide and is strongly influenced by modifiable risk factors, including blood pressure (BP), arterial stiffness, dyslipidaemia, and diet. Dairy proteins and emerging plant proteins have received increasing attention for their potential to improve cardiovascular risk via bioactive peptides, particularly those with angiotensin converting enzyme (ACE) -inhibitory activity. However, few studies have compared animal and plant protein sources across both mechanistic in vitro outcomes and in vivo clinical endpoints in at risk humans. This thesis aimed to determine whether hempseed protein extract (HPE), whey protein concentrate (WPC), and bovine colostrum (BC) could ameliorate CVD risk factors, with a primary focus on BP and indices of arterial stiffness.
An initial in vitro digestion study characterised protein solubility, amino acid profiles, electrophoretic patterns, and ACE-inhibitory activity of HPE, WPC, and BC across simulated gastric and intestinal phases. WPC displayed rapid gastric proteolysis and sustained ACE inhibition from gastric to intestinal digestion, consistent with the efficient generation of whey derived ACE inhibitory peptides. BC exhibited lower initial solubility but pronounced gastric phase peptide release and high ACE inhibition that declined in the intestinal phase, suggesting over digestion of potent peptides under these conditions. HPE remained comparatively insoluble but showed a progressive rise in ACE inhibition over digestion, reflecting slower peptide liberation from hemp proteins yet convergence to similar endpoint ACE-inhibitory activity as WPC and BC. Collectively, these data indicate that all three protein sources can yield ACE inhibitory peptides, albeit with distinct digestion patterns.
Two randomised controlled trials then evaluated the in vivo effects of these proteins in adults with increased CVD risk. The first trial examined 16 weeks of HPE supplementation versus control on office and central BP, 24 hr ambulatory BP, pulse wave analysis indices, and blood lipids. The second trial compared daily WPC and BC supplementation with control over 16 weeks using similar vascular and lipid outcomes. Both trials were designed around prior protein supplementation work in mildly hypertensive adults, with adaptations to dose, duration, and measurement protocols to enhance feasibility and capture arterial adaptations. Across both studies, supplementation with HPE and milk proteins produced modest but clinically relevant improvements in selected arterial indices and BP parameters, with patterns reflecting differences in protein source and baseline risk, although not all outcomes reached statistical significance.
Overall, this work showed that intact hemp and milk proteins can generate ACE inhibitory peptides in vitro and may favourably influence BP and arterial stiffness in adults with elevated CVD risk. HPE emerged as a promising, potentially more sustainable protein source with functional capacity approaching that of established dairy proteins, while BC demonstrated distinct digestion and vascular effects compared with WPC. These findings support further dose–response and long term trials and highlight the need for peptide level mechanistic investigations to optimise the use of dietary proteins in cardiovascular risk reduction.